Gentler chemo for seniors: DOROTHY trial aims to cut toxicity without sacrificing results

NCT ID NCT06042569

First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 25 times

Summary

This study is for women aged 65 and older with early-stage HER2-negative breast cancer. It tests whether a lower dose of the chemotherapy drugs docetaxel and cyclophosphamide can still be effective while causing fewer side effects and improving quality of life. About 174 participants will be enrolled to compare the standard dose with a reduced dose.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANATOMIC STAGE III BREAST CANCER AJCC V8 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • City of Hope Medical Center

    RECRUITING

    Duarte, California, 91010, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Dana-Farber Cancer Institute

    RECRUITING

    Boston, Massachusetts, 02215, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • University of Rochester

    RECRUITING

    Rochester, New York, 14642, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.